Differential gene expression in human lung adenocarcinomas and squamous cell carcinomas

Clinical Cancer Research

Volumn 8, Issue 4, 2002, Pages 1127-1138

  McDoniels Silvers, Amy L ^a   Nimri, Caramella F ^a   Stoner, Gary D ^b   Lubet, Ronald A ^c   You, Ming ^a,b  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 MACROGLOBULIN; CD31 ANTIGEN; COMPLEMENTARY DNA; DECORIN; FIBRONECTIN; LUNG SURFACTANT; PROTEIN C FOS; RIBOSOME PROTEIN; SCATTER FACTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR PROTEIN; UBIQUITIN CONJUGATING ENZYME;

ARTICLE; CELL ADHESION; CELL MIGRATION; CHROMOSOME XQ; CONTROLLED STUDY; CYTOSKELETON; DNA LIBRARY; DOT HYBRIDIZATION; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATION; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; LUNG SQUAMOUS CELL CARCINOMA; METASTASIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; UNINDEXED SEQUENCE;

ADENOCARCINOMA; AGED; CARCINOMA, SQUAMOUS CELL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE LIBRARY; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NUCLEIC ACID HYBRIDIZATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM;

EID: 0036554867     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (81)

1. Greenlee, R. T., Murray, T., Bolden, S., and Wingo, P. A. Cancer statistics, 2000. CA Cancer J. Clin, 50: 7-33, 2000.
2. Sekido, Y., Fong, K. M., and Minna, J. D. Progress in understanding the molecular pathogenesis of human lung cancer. Biochim. Biophys. Acta, 1378: F21-F59, 1998.
3. Schiller, J. H. Carcinoma of the lung. In: R. T. Skeel (ed.), Handbook of Cancer Chemotherapy, pp. 198-213. Philadelphia: Lippincott Williams & Wilkins, 1999.
4. Ioachim, H. L. Morphology of human carcinogenesis. Anticancer Res., 19: 4627-4643, 1999.
5. Robbins, S. L., Kumar, V., and Cotran, R. S. Lung cancer. In: F. J. Schoen (ed.), Pathological Basis of Disease, pp. 673-734. Philadelphia: W. B. Saunders Company, 1994.
6. Fong, K. M., Sekido, Y., and Minna, J. D. Molecular pathogenesis of lung cancer. J. Thorac. Cardiovasc. Surg., 118: 1136-1152, 1999.
7. Spivack, S. D., Fasco, M. J., Walker, V. E., and Kaminsky, L. S. The molecular epidemiology of lung cancer. Crit. Rev. Toxicol., 27: 319-365, 1997.
8. Fearon, E. R., and Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell, 61: 759-767, 1990.
9. Weinberg, R. A. Oncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis. Cancer Res., 49: 3713-3721, 1989.
10. Rachwal, W. J., Bongiomo, P. F., Orringer, M. B., Whyte, R. I., Ethier, S. P., and Beer, D. G. Expression and activation of erbB-2 and epidermal growth factor receptor in lung adenocarcinomas. Br. J. Cancer, 72: 56-64, 1995.
11. Harvey, P., Warn, A., Newman, P., Perry, L. J., Ball, R. Y., and Warn, R. M. Immunoreactivity for hepatocyte growth factor/scatter factor and its receptor, met, in human lung carcinomas and malignant mesotheliomas. J. Pathol., 180: 389-394, 1996.
12. Olivero, M., Rizzo, M., Madeddu, R., Casadio, C., Pennacchietti, S., Nicotra, M. R., Prat, M., Maggi, G., Arena, N., Natali, P. G., Comoglio, P. M., and Di Renzo, M. F. Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas. Br. J. Cancer, 74: 1862-1868, 1996.
13. Sekido, Y., Takahashi, T., Ueda, R., Takahashi, M., Suzuki, H., Nishida, K., Tsukamoto, T., Hida, T., Shimokata, K., Zsebo, K. M., and et al. Recombinant human stem cell factor mediates chemotaxis of small-cell lung cancer cell lines aberrantly expressing the c-kit protooncogene. Cancer Res., 53: 1709-1714, 1993.
14. Krystal, G. W., Hines, S. J., and Organ, C. P. Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. Cancer Res., 56: 370-376, 1996.
15. Richardson, G. E., and Johnson, B. E. The biology of lung cancer. Semin. Oncol., 20: 105-127, 1993.
16. Ruas, M., and Peters, G. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim. Biophys. Acta, 1378: F115-F177, 1998.
17. Kohno, T., and Yokota, J. How many tumor suppressor genes are involved in human lung carcinogenesis? Carcinogenesis (Lond.), 20: 1403-1410, 1999.
18. Schwendel, A., Langreck, H., Reichel, M., Schrock, E., Ried, T., Dietel, M., and Petersen I. Primary small-cell lung carcinomas and their metastases are characterized by a recurrent pattern of genetic alterations. Int. J. Cancer, 74: 86-93, 1997.
19. Testa, J. R., Liu, Z., Feder, M., Bell, D. W., Balsara, B., Cheng, J. Q., and Taguchi, T. Advances in the analysis of chromosome alterations in human lung carcinomas. Cancer Genet. Cytogenet., 95: 20-32, 1997.
20. Wang, Y., Hu, L., Yao, R., Crist, K. A., Grubbs, G. J., Lubet, R. A., and You, M. Altered gene expression profile in chemically induced rat mammary adenocarcinomas and its modulation by an aromatase inhibitor. Oncogene, 20: 7710-7721, 2001.
21. Sambrook, J., Fritsch, E. F., and Maniatis, T. Small-scale preparations of plasmid DNA. In: N. Ford (ed.), Molecular Cloning: A Laboratory Manual, pp. 1.25-21.28. New York: Cold Springs Harbor Laboratory, 1989.
22. Altschul, S. F., Madden, T. L., Schaffer, A. A., Zhang, J., Zhang, Z., Miller, W., and Lipman, D. J. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res., 25: 3389-3402, 1997.
23. Varmus, H. Oncogenes and the Molecular Origins of Cancer, pp. 3-44. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory, 1989.
24. Liang, P., and Pardee, A. B. Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science (Wash. DC), 257: 967-971, 1992.
25. Levitzky, M. G. Mechanics of breathing. In: Pulmonary Physiology, pp. 13-54. New York: McGraw-Hill, Inc., 1999.
26. Korutla, L., and Strayer, D. S. SP-A as a cytokine: surfactant protein-A-regulated transcription of surfactant proteins and other genes. J. Cell. Physiol., 178: 379-386, 1999.
27. Smith, M. J., Rousculp, M. D., Goldsmith, K. T., Curiel, D. T., and Garver, R. I., Jr. Surfactant protein A-directed toxin gene kills lung cancer cells in vitro. Hum. Gene Ther., 5: 29-35, 1994.
28. Linnoila, R. I., Mulshine, J. L., Steinberg, S. M., and Gazdar, A. F. Expression of surfactant-associated protein in non-small-cell lung cancer: a discriminant between biologic subsets. J. Natl. Cancer Inst. Monogr., 13: 61-66, 1992.
29. Khoor, A., Whitsett, J. A., Stahlman, M. T., and Halter, S. A. Expression of surfactant protein B precursor and surfactant protein B mRNA in adenocarcinoma of the lung. Mod. Pathol., 10: 62-67, 1997.
30. Kaufmann, O., and Dietel, M. Thyroid transcription factor-1 is the superior immunohistochemical marker for pulmonary adenocarcinomas and large cell carcinomas compared to surfactant proteins A and B. Histopathology (Oxf.), 36: 8-16, 2000.
31. Manda, R., Kohno, T., Matsuno, Y., Takenoshita, S., Kuwano, H., and Yokota, J. Identification of genes (SPON2 and C20orf2) differentially expressed between cancerous and noncancerous lung cells by mRNA differential display. Genomics, 61: 5-14, 1999.
32. Schraml, P., Shipman, R., Colombi, M., and Ludwig, C. U. Identification of genes differentially expressed in normal lung and non-small cell lung carcinoma tissue. Cancer Res., 54: 5236-5240, 1994.
33. Pilling, A. M., Mifsud, N. A., Jones, S. A., Endersby-Wood, H. J., and Turton, J. A. Expression of surfactant protein mRNA in normal and neoplastic lung of B6C3FI mice as demonstrated by in situ hybridization. Vet. Pathol., 36: 57-63, 1999.
34. Re, F. C., Manenti, G., Borrello, M. G., Colombo, M. P., Fisher, J. H., Pierotti, M. A., Della Porta, G., and Dragani, T. A. Multiple molecular alterations in mouse lung tumors. Mol. Carcinog., 5: 155-160, 1992.
35. Roman, J. Fibronectin and fibronectin receptors in lung development. Exp. Lung Res., 23: 147-159, 1997.
36. Ruoslahti, E. Fibronectin. J. Oral. Pathol., 10: 3-13, 1981.
37. Hynes, R. O., Destree, A. T., Perkins, M. E., and Wagner, D. D. Cell surface fibronectin and oncogenic transformation. J. Supramol. Struct., 11: 95-104, 1979.
38. Vaheri, A., and Mosher, D. F. High molecular weight, cell surface-associated glycoprotein (fibronectin) lost in malignant transformation. Biochim. Biophys. Acta, 516: 1-25, 1978.
39. Tsukita, S., and Furuse, M. Occludin and claudins in tight-junction strands: leading or supporting players? Trends Cell Biol., 9: 268-273, 1999.
40. Gebbink, M. F., van Etten, I., Hateboer, G., Suijkerbuijk, R., Beijersbergen, R. L., Geurts van Kessel, A., and Moolenaar, W. H. Cloning, expression and chromosomal localization of a new putative receptor-like protein tyrosine phosphatase. FEBS Lett., 290: 123-130, 1991.
41. Brady-Kalnay, S. M., Mourton, T., Nixon, J. P., Pietz, G. E., Kinch, M., Chen, H., Brackenbury, R., Rimm, D. L., Del Vecchio, R. L., and Tonks, N. K. Dynamic interaction of PTPmu with multiple cadherins in vivo. J. Cell Biol., 141: 287-296, 1998.
42. Gould, K. L., Bretscher, A., Esch, F. S., and Hunter, T. cDNA cloning and sequencing of the protein-tyrosine kinase substrate, ezrin, reveals homology to band 4.1. EMBO J., 8: 4133-4142, 1989.
43. Turunen, O., Wahlstrom, T., and Vaheri, A. Ezrin has a COOH-terminal actin-binding site that is conserved in the ezrin protein family. J. Cell Biol., 126: 1445-1453, 1994.
44. Mangeat, P., Roy, C., and Martin, M. ERM proteins in cell adhesion and membrane dynamics. Trends Cell Biol., 9: 187-192, 1999.
45. Vaheri, A., Carpen, O., Heiska, L., Helander, T. S., Jaaskelainen, J., Majander-Nordenswan, P., Sainio, M., Timonen, T., and Turunen, O. The ezrin protein family: membrane-cytoskeleton interactions and disease associations. Curr. Opin. Cell Biol., 9: 659-666, 1997.
46. Toyama-Sorimachi, N., Sorimachi, H., Tobita, Y., Kitamura, F., Yagita, H., Suzuki, K., and Miyasaka, M. A novel ligand for CD44 is serglycin, a hematopoietic cell lineage-specific proteoglycan. Possible involvement in lymphoid cell adherence and activation. J. Biol. Chem., 270: 7437-7444, 1995.
47. Galvin, J. P., Spaeny-Dekking, L. H., Wang, B., Seth, P., Hack, C. E., and Froelich, C. J. Apoptosis induced by granzyme B-glycosaminoglycan complexes: implications for granule-mediated apoptosis in vivo. J. Immunol., 162: 5345-5350, 1999.
48. Mantovani, A., Bottazzi, B., Colotta, F., Sozzani, S., and Ruco, L. The origin and function of tumor-associated macrophages. Immunol. Today, 13: 265-270, 1992.
49. Stafford, S., Li, H., Forsythe, P. A., Ryan, M., Bravo, R., and Alam, R. Monocyte chemotactic protein-3 (MCP-3)/fibroblast-induced cytokine (FIC) in eosinophilic inflammation of the airways and the inhibitory effects of an anti-MCP-3/FIC antibody. J. Immunol., 158: 4953-4960, 1997.
50. Fioretti, F., Fradelizi, D., Stoppacciaro, A., Ramponi, S., Ruco, L., Minty, A., Sozzani, S., Garlanda, C., Vecchi, A., and Mantovani, A. Reduced tumorigenicity and augmented leukocyte infiltration after monocyte chemotactic protein-3 (MCP-3) gene transfer: perivascular accumulation of dendritic cells in peritumoral tissue and neutrophil recruitment within the tumor. J. Immunol., 161: 342-346, 1998.
51. Hedrick, S. M. Dawn of the hunt for nonclassical MHC function. Cell, 70: 177-180, 1992.
52. Rosa, F., Fellous, M., Dron, M., Tovey, M., and Revel, M. Presence of an abnormal β 2-microglobulin mRNA in Daudi cells: induction by interferon. Immunogenetics, 17: 125-131, 1983.
53. D'Urso, C. M., Wang, Z. G., Cao, Y., Tatake, R., Zeff, R. A., and Ferrone, S. Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression. J. Clin. Investig., 87: 284-292, 1991.
54. Bicknell, D. C., Rowan, A., and Bodmer, W. F. β 2-microglobulin gene mutations: a study of established colorectal cell lines and fresh tumors. Proc. Natl. Acad. Sci. USA, 91: 4751-4756, 1994.
55. Huang, C. N., Tsai, J. L., Chen, M. T., Wu, W. J., Kuo, K. W., and Huang, C. H. Changes in the activities of mitochondrial enzymes in the progress of tumorigenesis of bladder cancer. Biochem. Mol. Biol. Int., 46: 375-383, 1998.
56. Sharp, M. G., Adams, S. M., Walker, R. A., Brammar, W. J., and Varley, J. M. Differential expression of the mitochondrial gene cytochrome oxidase II in benign and malignant breast tissue. J. Pathol., 168: 163-168, 1992.
57. LaBiche, R. A., Demars, M., and Nicolson, G. L. Transcripts of the mitochondrial gene ND5 are overexpressed in highly metastatic murine large cell lymphoma cells. In Vivo, 6: 317-324, 1992.
58. Wong, T. W., Yu, H. Y., Kong, S. K., Fung, K. P., and Kwok, T. T. The decrease of mitochondrial NADH dehydrogenease and drug induced apoptosis in doxorubicin resistant A431 cells. Life Sci., 67: 1111-1118, 2000.
59. Mullauer, L., Suzuki, H., Fujita, H., Katabami, M., and Kuzumaki, N. Identification of genes that exhibit increased expression after flat reversion of NIH/3T3 cells transformed by human activated Ha-ras oncogene. Cancer Lett., 59: 37-43, 1991.
60. Stander, M., Naumann, U., Wick, W., and Weller, M. Transforming growth factor-β and p-21: multiple molecular targets of decorin-mediated suppression of neoplastic growth. Cell Tissue Res., 296: 221-227, 1999.
61. Weller, M., and Fontana, A. The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-β. T-cell apoptosis, and the immune privilege of the brain. Brain Res. Brain Res. Rev., 21: 128-151, 1995.
62. Vanky, F., Nagy, N., Hising, C., Sjovall, K., Larson, B., and Klein, E. Human ex vivo carcinoma cells produce transforming growth factor β and thereby can inhibit lymphocyte functions in vitro. Cancer Immunol. Immunother., 43: 317-323, 1997.
63. Munoz-Antonia, T., Li, X., Reiss, M., Jackson, R., and Antonia, S. A mutation in the transforming growth factor β type II receptor gene promoter associated with loss of gene expression. Cancer Res., 56: 4831-4835, 1996.
64. Liu, C., Adamson, E., and Mercola, D. Transcription factor EGR-1 suppresses the growth and transformation of human HT-1080 fibrosarcoma cells by induction of transforming growth factor β 1. Proc. Natl. Acad. Sci. USA, 93: 11831-11836, 1996.
65. Liu, C., Yao, J., de Belle, I., Huang, R. P., Adamson, E., and Mercola, D. The transcription factor EGR-1 suppresses transformation of human fibrosarcoma HT 1080 cells by coordinated induction of transforming growth factor-β1, fibronectin, and plasminogen activator inhibitor-1. J. Biol. Chem., 274: 4400-4411, 1999.
66. Levin, W. J., Press, M. F., Gaynor, R. B., Sukhatme, V. P., Boone, T. C., Reissmann, P. T., Figlin, R. A., Holmes, E. C., Souza, L. M., and Slamon, D. J. Expression patterns of immediate early transcription factors in human non-small cell lung cancer. The Lung Cancer Study Group. Oncogene, 11: 1261-1269, 1995.
67. Huang, R. P., Fan, Y., de Belle, I., Niemeyer, C., Gottardis, M. M., Mercola, D., and Adamson, E. D. Decreased Egr-1 expression in human, mouse and rat mammary cells and tissues correlates with tumor formation. Int. J. Cancer, 72: 102-109, 1997.
68. Shimo, T., Nakanishi, T., Nishida, T., Asano, M., Kanyama, M., Kuboki, T., Tamatani, T., Tezuka, K., Takemura, M., Matsumura, T., and Takigawa, M. Connective tissue growth factor induces the proliferation, migration, and tube formation of vascular endothelial cells in vitro, and angiogenesis in vivo. J Biochem (Tokyo), 126: 137-145, 1999.
69. Kubo, M., Kikuchi, K., Nashiro, K., Kakinuma, T., Hayashi, N., Nanko, H., and Tamaki, K. Expression of fibrogenic cytokines in desmoplastic malignant melanoma. Br. J. Dermatol., 139: 192-197, 1998.
70. Nishida, T., Nakanishi, T., Shimo, T., Asano, M., Hattori, T., Tamatani, T., Tezuka, K., and Takigawa, M. Demonstration of receptors specific for connective tissue growth factor on a human chondrocytic cell line (HCS-2/8). Biochem. Biophys. Res. Commun., 247: 905-909, 1998.
71. Wenger, C., Ellenrieder, V., Alber, B., Lacher, U., Menke, A., Hameister, H., Wilda, M., Iwamura, T., Beger, H. G., Adler, G., and Gress, T. M. Expression and differential regulation of connective tissue growth factor in pancreatic cancer cells. Oncogene, 18: 1073-1080, 1999.
72. Igarashi, A., Hayashi, N., Nashiro, K., and Takehara, K. Differential expression of connective tissue growth factor gene in cutaneous fibrohistiocytic and vascular tumors. J. Cutan. Pathol., 25: 143-148, 1998.
73. Newman, P. J. Switched at birth: a new family for PECAM-1. J. Clin. Investig., 103: 5-9, 1999.
74. Ferrero, E., Ferrero, M. E., Pardi, R., and Zocchi, M. R. The platelet endothelial cell adhesion molecule-1 (PECAM1) contributes to endothelial barrier function. FEBS Lett., 374: 323-326, 1995.
75. Paulson, R. F., Vesely, S., Siminovitch, K. A., and Bernstein, A. Signalling by the W/Kit receptor tyrosine kinase is negatively regulated in vivo by the protein tyrosine phosphatase Shp1. Nat. Genet., 13: 309-315, 1996.
76. Lorenz, U., Bergemann, A. D., Steinberg, H. N., Flanagan, J. G., Li, X., Galli, S. J., and Neel, B. G. Genetic analysis reveals cell type-specific regulation of receptor tyrosine kinase c-Kit by the protein tyrosine phosphatase SHP1. J. Exp. Med., 184: 1111-1126, 1996.
77. Isaac, L., Florido, M. P., Fecchio, D., and Singer, L. M. Murine α-2-macroglobulin increase during inflammatory responses and tumor growth. Inflamm. Res., 48: 446-452, 1999.
78. Barrett, A. J., and Starkey, P. M. The interaction of α 2-macroglobulin with proteinases. Characteristics and specificity of the reaction, and a hypothesis concerning its molecular mechanism. Biochem J., 133: 709-724, 1973.
79. Gonias, S. L. α 2-macroglobulin: a protein at the interface of fibrinolysis and cellular growth regulation. Exp. Hematol., 20: 302-311, 1992.
80. Marchandise, F. X., Mathieu, B., Francis, C., and Sibille, Y. Local increase of antiprotease and neutrophil elastase-α 1-proteinase inhibitor complexes in lung cancer. Eur. Respir. J., 2: 623-629, 1989.
81. Smorenburg, S. M., Griffini, P., Tiggelman, A. B., Moorman, A. F., Boers, W., and Van Noorden, J. F. α2-Macroglobulin is mainly produced by cancer cells and not by hepatocytes in rats with colon carcinoma metastases in liver. Hepatology, 23: 560-570, 1996.